ERBB2 and breast carcinoma: To assess the efficacy of combining trastuzumab and niraparib treatments on HER2+ breast cancer cells, percent survival curves were established with increasing concentrations of trastuzumab (0.1–100 μg/mL) or niraparib (0.1–100 μM).